2.7054

0.19% 0.0104

Anavex Life Sciences Corp (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corp stock is traded at $2.7054, with a volume of 410.14K. It is up +0.19% in the last 24 hours and down -19.16% over the past month. Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Previous Close:

$2.695

Open:

$2.69

24h Volume:

410.14K

Relative Volume:

0.31

Market Cap:

$250.68M

Revenue:

Net Income/Loss:

$-39.95M

P/E Ratio:

-5.8193

EPS:

-0.4649

Net Cash Flow:

$-34.08M

1W Performance:

+1.13%

1M Performance:

-19.16%

6M Performance:

-30.05%

1Y Performance:

-64.14%

1-Day Range:

$2.69

$2.80

1-Week Range:

$2.635

$2.80

52-Week Range:

$2.61

$13.99

Anavex Life Sciences Corp Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corp

Sector

Healthcare (1110)

Industry

Biotechnology (618)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2026-05-26

Latest SEC Filings

AVXL's Discussions on Twitter

Compare AVXL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVXL Anavex Life Sciences Corp	2.705	249.75M	0	-39.95M	-34.08M	-0.4649
VRTX Vertex Pharmaceuticals Inc	437.44	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	641.12	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.12	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.14	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.26	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Anavex Life Sciences Corp Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corp Stock (AVXL) Latest News

May 22, 2026

Anavex Life Sciences receives Nasdaq delisting warning By Investing.com - Investing.com South Africa

May 22, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 22, 2026

Anavex Life Sciences receives expected Nasdaq delinquency notification - marketscreener.com

May 22, 2026

Anavex Life Sciences Received Notice of Noncompliance - TradingView

May 22, 2026

Nasdaq warns Anavex (Nasdaq: AVXL) over delayed quarterly filing - Stock Titan

May 22, 2026

Anavex Life Sciences Corp. Receives Delinquency Notification from Nasdaq for Non-Compliance with Listing Rule - Quiver Quantitative

May 22, 2026

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification - Anavex Life Sciences

May 22, 2026

Nasdaq flags Anavex for missing 10-Q, gives July 20 fix date - Stock Titan

May 22, 2026

May 18, 2026

AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill

May 18, 2026

May 17, 2026

Anavex Life Sciences stock crushed as European Alzheimer's drug filing pulled after EMA pushback - MSN

May 17, 2026

May 16, 2026

Anavex Life Sciences Announces COO Departure Amid Restructuring - The Globe and Mail

May 16, 2026

May 15, 2026

Anavex (AVXL) COO exits amid reorganization; option grant largely forfeited - Stock Titan

May 15, 2026

May 14, 2026

Anavex (AVXL) interim CEO discloses detailed stock option grants - Stock Titan

May 14, 2026

Anavex withdraws EU approval filing for Alzheimer’s therapy - MSN

May 14, 2026

Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug? - MSN

May 14, 2026

May 13, 2026

AVXL stock tanks after Anavex withdraws EU bid for Alzheimer's drug - MSN

May 13, 2026

May 12, 2026

Anavex Delays Quarterly Filing Amid CEO Shake-Up - The Globe and Mail

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 11, 2026

Anavex Life Sciences (AVXL) Delays Quarterly Report Submission - GuruFocus

May 11, 2026

AVXL SEC FilingsAnavex Life Scie 10-K, 10-Q, 8-K Forms - Stock Titan

May 11, 2026

Anavex Life Sciences (NASDAQ: AVXL) delays 10-Q after CEO termination - Stock Titan

May 11, 2026

May 09, 2026

MSN Money - MSN

May 09, 2026

May 08, 2026